Replies to post #1376 on IDM Pharma, Inc. (IDMI)

[bowonwing]

the "iceberg" is Mepact approval in Europe, however many tips of the iceberg there might be.

However, I do find it interesting that BMY is paying $240M in 2008 and 2009 to EXEL in their partnership, and the equivalent price for the whole company of IDM is $8.50 a share. That does not make sense to me at this point.

(We will use 28M shares outstanding for IDMI (which is on the high side- just to be safe):
28M x $8.50 a share= $238M market cap)